Genentech withdraws psoriasis drug Raptiva in US over PML risk
This article was originally published in Scrip
Genentech is to withdraw its psoriasis therapy Raptiva (efalizumab) in the US based on its association with an increased risk of developing progressive multifocal leucoencephalopathy (PML), a rare and potentially fatal brain infection.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.